Published in Lab Business Week, July 17th, 2005
The method is based on a mathematical model that determines when a cancer becomes drug-resistant during therapy. It does this by estimating the probability of finding drug-resistant mutant cells at different stages of cancer progression and examining the fate of individual mutant colonies during therapy. It then pinpoints under what circumstances these mutant cells become a problem and the therapy stops being effective. The finding will help physicians...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.